Repository logo

Browsing by Author "Aguiar, Pedro N., Jr."

Now showing 1 - 2 of 2
  • A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker
    Publication . Aguiar, Pedro N., Jr.; Santoro, Ilka Lopes; Tadokoro, Hakaru; Lopes, Gilberto de Lima; Filardi, Bruno Andraus; Oliveira, Pedro; Castelo-Branco, Pedro; Mountzios, Giannis; de Mello, Ramon Andrade
    Background: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
    2016-09Journal article Restricted Show more
  • PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
    Publication . Aguiar, Pedro N., Jr.; De Mello, Ramon Andrade; Hall, Peter; Tadokoro, Hakaru; de Lima, Gilberto
    Aim: The treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is the tumor programmed death ligand one (PD-L1) expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data. Methods: We searched in network and conference data sources for relevant clinical studies of immunotherapy for non-small-cell lung cancer that assessed the PD-L1 expression even as an exploratory analysis. The updated survival hazard ratios (HR) were included in the analysis. Results: 14 studies with 2857 patients were included (2019 treated with immunotherapy). The response rate was as higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89). Conclusion: PD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors.
    2017-05Journal article Restricted Show more